Stock screener

GLUE

Conviction 4HealthcareScan · Thu, Sep 24, 2026

Monte Rosa Therapeutics, Inc. (GLUE) closed at $11.74 (-1.26%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 28, RS Rating 94, -53.6% from its 52-week high, -23.3% year to date. Sector: Healthcare · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES).

GLUE$11.74-1.26%
ResistanceSupportVol 14Insider sell
63 bars
2
2
Vol MA14 1.26M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Monte Rosa Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.monterosatx.com ↗
Price11.74
Change-1.26%
Gap+0.00%
Rel volume0.97×
Avg volume1.18M
Avg $ vol15.78M
SMA 2013.40
SMA 5016.27
SMA 20018.36
Price vs 50-27.83%
Price vs 200-36.04%
MA stackbearish
50/200 cross—
Supertrenddown · 13.76
RSI (14)28
MACD hist-0.02
MACD crossbear · 1d
Stoch %K / %D9 / 11
ADX (14)35
+DI / −DI15 / 34
RSI divergence—
MACD divergence—
ATR %6.55%
ADR %5.17%
52w high25.31
52w low6.55
From 52w high-53.62%
Above 52w low+79.24%
New 52w highNo
SqueezeOff
Bollinger width27.35%
%B0.05
Donchian pos8.68%
Donchian high15.00
Donchian low11.43
AVWAP (52w high)18.77
vs AVWAP high-37.45%
AVWAP (52w low)17.71
vs AVWAP low-33.71%
OBV trendDown
Chaikin MF (20)-0.11
Today vs 20d0.97×
Avg vol (14d)1.26M
Avg vol (20d)1.18M
Avg $ vol (20d)15.78M
Market cap1B
RS Rating94 / 99
RS 3m (vs SPY)-50.29%
RS 6m (vs SPY)-42.09%
RS line new highNo
Trend template1/8
Technical rank10.0
1 week-6.83%
1 month-19.37%
3 months-45.80%
6 months-25.27%
1 year+85.47%
YTD-23.32%
P/E-25.93
P/B2.06
P/S8.10
P/FCF-36.42
EPS-2.96
Div yield—
ROE-7.93%
ROA-5.59%
Debt/Eq—
Current10.58
EV/EBITDA—
Gross margin—
Net margin-31.23%
Rev growth63.54%
EPS growth46.87%
Price target30.80
Target upside162.35%
Analyst ratingBuy
Institutional112.81%
Ent. value911.48M
Revenue8.97M
Net income-43.4M
Gross profit—
Free cash flow-27.5M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out84.48M
Employees161
ListedThu, Jun 24, 2021
Free float49.32M
Float %75.7%
Short interest18.08M
Days to cover16.6d
Short volume28.7%
Squeeze score65 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.43 vs −$0.25
Last surprise-72.0% miss
Setup gradeD
Conviction4 / 100
Pattern quality—
Tech rank10.0 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance16.24
Support12.57
Days since event—
Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in GLUE

All disclosures →
No recent disclosed trades by Congress in GLUE. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in GLUE · open-market 5 sells

InsiderSideShares
Warmuth Markus
President & CEO · Common Stock · 2026-07-16
Sell9.5K
Champoux Jennifer
Chief Operating Officer · Stock Option (Right to Buy) · 2026-07-15
Exercise4.35K
Champoux Jennifer
Chief Operating Officer · Common Stock · 2026-07-15
Exercise4.35K
Champoux Jennifer
Chief Operating Officer · Common Stock · 2026-07-15
Sell4.35K
Townson Sharon
Chief Scientific Officer · Common Stock · 2026-07-06
Sell5.6K
Townson Sharon
Chief Scientific Officer · Stock Option (Right to Buy) · 2026-07-06
Exercise6K
Townson Sharon
Chief Scientific Officer · Common Stock · 2026-07-06
Exercise6K
Townson Sharon
Chief Scientific Officer · Common Stock · 2026-07-06
Sell400
Manning Anthony M.
Director · Common Stock · 2026-06-29
Sell10K
Manning Anthony M.
Director · Stock Option (Right to Buy) · 2026-06-29
Exercise10K

SEC filings

EDGAR filings in GLUE · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.